Fibroblast Growth Factor 23, Klotho, and Disordered Mineral Metabolism in Chronic Kidney Disease: Unraveling the Intricate Tapestry of Events and Implications for Therapy-Reference-Cited by-同舟云学术

Fibroblast Growth Factor 23, Klotho, and Disordered Mineral Metabolism in Chronic Kidney Disease: Unraveling the Intricate Tapestry of Events and Implications for Therapy

Published:2013-05 Issue:3 Volume:23 Page:250-254
ISSN:1051-2276
Container-title:Journal of Renal Nutrition
language:en
Short-container-title:Journal of Renal Nutrition

Author:

Gutiérrez Orlando M.

Publisher

Elsevier BV

Subject

Nephrology,Nutrition and Dietetics,Medicine (miscellaneous)

Reference36 articles.

1. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism;Quarles;Nat Rev Endocrinol,2012

2. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production;Saito;J Biol Chem,2003

3. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate;Bowe;Biochem Biophys Res Commun,2001

4. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D;Liu;J Am Soc Nephrol,2006

5. The parathyroid is a target organ for FGF23 in rats;Ben-Dov;J Clin Invest,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the association between serum antiaging humoral factor klotho and cardiovascular disease potential risk factor apolipoprotein B in general population;Medicine;2023-06-23

2. 1,25-dihydroxyvitamin D as Predictor of Renal Worsening Function in Chronic Kidney Disease. Results From the PASCaL-1,25D Study;Frontiers in Medicine;2022-03-02

3. Toxines urémiques de moyen poids moléculaire : un véritable regain d’intérêt;Néphrologie & Thérapeutique;2019-04

4. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment;Endocrine Reviews;2018-01-26

5. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy;Kidney International;2017-05